Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency
Growth Hormone Deficiency
About this trial
This is an interventional basic science trial for Growth Hormone Deficiency focused on measuring insulin sensitivity, substrate metabolism, fatty liver, intramyocellular lipids, growth hormone deficiency, Growth hormone deficiency (Adult)
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Must be of legal age and competent
- Age: >18 and <60 years old
- Presently diagnosed with growth hormone deficiency; if panhypopituitary, the patient must be sufficiently substituted in the other axis´s, for at least 3 months before inclusion in the study
Exclusion Criteria:
- Alcohol consumption >21 units per week
- Malignant disease
- Pregnancy
- Magnetic implants or material in the body
- Claustrophobia
- BMI >30
- Heart disease (NYHA >2)
- Uncontrolled hypertension
- Manifest diabetes mellitus
- Change in medication, with any influence on glucose metabolism, 2 months prior to and until the end of the trial.
Controls are matched on age, gender and BMI
Inclusion Criteria:
- Written informed consent
- Must be of legal age and competent
Exclusion Criteria:
- Alcohol consumption >21 units per week
- Malignant disease
- Pregnancy
- Magnetic implants or material in the body
- Claustrophobia
- Heart disease (NYHA >2)
- Uncontrolled hypertension
- Manifest diabetes mellitus
- Change in medication, with any influence on glucose metabolism, 2 months prior to and until the end of the trial
Sites / Locations
- Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Sygehus, Denmark.
- Medical Department M, Aarhus University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
a
Control
the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.